Postmenopausal estrogen replacement therapy and increased rates of cholecystectomy and appendectomy

CMAJ. Canadian Medical Association Journal

Volumn 162, Issue 10, 2000, Pages 1421-1424

  Mamdani, Muhammad M ^a,b   Tu, Karen ^c   Van Walraven, Carl ^d   Austin, Peter C ^e   David Naylor, C ^f,g  

^a INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^b Faculties of Pharmacy   (Canada)

^c Medicine

^d Department of Public Health Sciences ^*

^e UNIVERSITY OF TORONTO   (Canada)

^f TORONTO WESTERN HOSPITAL   (Canada)

^g UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE DERIVATIVE; ESTROGEN; LEVOTHYROXINE;

AGED; APPENDECTOMY; APPENDICITIS; ARTICLE; CHOLECYSTECTOMY; CHOLECYSTITIS; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DRUG UTILIZATION; ESTROGEN THERAPY; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; POSTMENOPAUSE; TREATMENT INDICATION;

EID: 0034673994     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Lanliisch PG, Droge AI, Gottesleben F. Drug induced acute pancreatitis: incidence and severity. Gut 1995;37:565-7.
2. Aleier CR, Sturkenboom AIC, Cohen AS, Jick II. Postmenopausal estrogen replacement therapy and the risk of developing systemic lupus erythematosus or discoid \upus.JRheumaul 1998;2S:151S-9.
3. Troisi RJ, Speizer FE, Willett WC, Trichopoulos D, Rosner B. Alenopause, postmenopausal estrogen preparations, and the risk of adult-onset asthma: a prospective cohort study. AmJRespir Crit Care Meet 1995;152:1183-8.
4. LeResche L, Saunders K, Von Korff AIR, Barlow W, Dworkin SF. Use of exogenous hormones and risk of temporomandibular disorder pain. Pain 1997;69:153-60.
5. Ansbacher R. Oral estrogen replacement and abdominal pain: a report of two cases. JReproJMeJ I984;29:881-2.
6. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (IIERS) Research Group. JAMA 1998;280:605-I3.
7. Grodstein F, Colditz GA, Stampfer A1J. Postmenopausal hormone use and cholecystectomy in a large prospective study. Obstet Gynccol 1994;83:5-11.
8. Everson RB, Byar DP, Bischoff AJ. Estrogen predisposes to cholecystectomy but not to stones. Gastroenterology 1982;82:4-8.
9. Cushman AI, Aleilahn EN, Psaty BM, Kuller LH, Dobs AS, Tracy RP. I lormone replacement therapy, inflammation, and hemostasis in elderly women. ArtcriosclcrTbromb Vase Bid 1999;I9(4):893-9.
10. Alogil JS, Sternberg WF, Kest B, Alarek P, Liebeskind JC. Sex differences in the antagonism of swim-stress analgesia: effects of gonadectomy and estrogen replacement. Pain 1993;S3:17-25.
11. Ridker PAI, Hennekens CH, Rifai N, Buring JE, Alanson JE. Hormone relacement therapy and increased plasma concentration of C-reactive protein. Circulation 1999; 100:713-6.
12. Cushman AI, Legault C, Barrett-Connor E, Stefanick AIL, Kessler C, Judd I IL, et al. Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation 1999;IOO:717-22.
13. Villabianca AC, Hanley AIR. 17beta-estradiol stimulates substance P receptor gene expression. Mol Cell Endocrine! 1997;135(2):109-17.
14. Negus SS, Alello NK. Opioid antinociception in ovariectomized monkeys: comparison with antinociception in males and effects of estradiol replacement. J Piarmacol Exp Tber 1999;290(3):1132-40.
15. Canadian classification of diagnostic, therapeutic, and surgical procedures. Ottawa: Statistics Canada; 1993. Cat no 82-562.
16. Williams JI, Young W. A summary of studies on the quality of health care administrative databases in Canada. In: Goel V, TOlliams JI, Andersen GM, BlacksteinHirsh P, Fooks C, Naylor CD, editors. Patterns of health care in Ontario. The ICES practice atlas. 2nd ed. Ottawa: Canadian Aledical Association; 1996. p. 339-45.
17. Rawson NS, Alalcolm E. Validity of the recording ofchulecystectojny and hysterectomy in the Saskatchewan Health Care datafiles. Saskatoon: Phannacoepidemiology Research Consortium; 1995.
18. Dennison EAI, Arden NK, Kellingray S, Croft P, Coggon D, Cooper C. Hormone replacement therapy, other reproductive variables, and symptomatic hip osteoarthritis in elderly white women: a case-control study. Br J Rheumatol 1998;37:1198-202.
19. Matthews K, Kuller L, Wing R, Aleilahn E, Plantingra P. Prior to use of estrogen replacement therapy, are users healthier than nonusers? Am J Epi/o/I996;143:971-8.
20. Rödström K, Bengtsson C, Lissner L, Björkelund C. Pre-existing risk factor profiles in users and non-users of hormone replacement therapy: prospective cohort study in Gothenburg, Sweden. BMJ 1999;319:890-3.
21. Alartinez de Pancorbo C, Carballo F, Horcajo P. Prevalence and associated factors for gallstone disease: results of a population survey in Spain. J Clin Epidemiol 1997;50(12):1347-55.
22. Leitzmann A1F, Willett WC, Rimm EB, Stampfer AIJ, Spiegelman D, Colditz GA, et al. A prospective study of coffee consumption and the risk of symptomatic gallstone disease in men. JAMA 1999;281(22):2106-12.